This pathogenic BRAF V600E mutation is an oncogenic driver in many melanomas, colon, thyroid and NSCLC cancers and is a drug target for BRAF inhibitors including vemurafenib, dabrafenib and encorafenib [4]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.